Albina Gosmanova, MD
Assistant Professor |
|
 |
Mailing Address:
920 Stanton L. Young Blvd., WP 1343
Oklahoma City, OK 73104-5020 |
Telephone:
(405) 271-5896 ext 47730
Fax:
(405) 271-7522 |
| Email: albina-gosmanova@ouhsc.edu |

Professional Interests
- Diabetes and its complications

Education
| 2004-2007 |
Fellowship: Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK |
| 2001-2004 |
Residency, Primary Care Medicine Residency Program: Unity Health System, Department of Internal Medicine, Rochester, New York |
| 2000 |
Clinical Observership: Primary Care Medicine Residency Program, Unity Health System/Park Ridge Hospital, Department of Internal Medicine, Rochester, New York |
| 1997-1998 |
Residency: Department of Internal Medicine, Kazan State Medical Academy |
| 1995-1996 |
Internship: Department of Internal Medicine, Kazan State Medical University |
| 1989-1995 |
MD - Kazan State Medical University, Tatarstan, Russia |

Niyaz Gosmanov, Albina Gosmanova, Holly Hull, David Fields “Differences in Trunk Fat-Free Content between Caucasian and African-American Young Healthy Females with a Similar Waist Circumference, Body Mass Index and Toal Percent Body Fat” Poster Presentation at the American Diabetes Association’s 67th Scientific Sessions, June 22-26, 2007 in Chicago, IL. Will be published in June supplement to the journal Diabetes.
Gosmanova AK, Alaupovic P, Knight-Gibson C, Lyons TJ, Characterization of type 1 and type 2 diabetes by apolipoprotein-defined lipoprotein subclasses. Diabetes 55 (Suppl 1); A201, 2006.

Oral Presentations
Albina K Gosmanova, Kangmo Lu, Niyaz R Gosmanov, Christopher E Aston, Jian-Xing Ma and Timothy J Lyons. “Plasma PEDF concentration in diabetic patients and in relation to statin therapy” Poster Presentation at ENDO 2007, The Endocrine Society’s 89th Annual Meeting, June 2 - 5 in Toronto, Canada.

Poster Presentations
Albina Gosmanova. Oral presentations at Southern Society of Clinical investigators, Atlanta, GA March,2006:
1. “Characterization of type I and type II diabetes by apolipoprotein-defined lipoprotein subclasses”
2. “Characterization of Metabolic Syndrome by Apolipoprotein-defined Lipoprotein Subclasses”
|